First European case of convulsions related to analytically confirmed use of the synthetic cannabinoid receptor agonist AM-2201
There is increasing reported use of synthetic cannabinoid receptor agonists (SCRA) across Europe. To date, there is limited information on the acute toxicity (harm) related to the use of these products. We describe here a case in which an individual developed convulsions related to the use of the SCRA AM-2201.
A 20 year old male smoked a "Spice" (SCRA-containing) product called “Black Mamba,” and rapidly after smoking, he had a generalised self-terminating tonic-clonic convulsion. After a 2 h observation period in the Emergency Department (ED), he self-discharged against medical advice. Subsequent analysis of urine collected at the time of presentation to the ED detected metabolites of AM-2201; no other drugs were detected on extensive analytic screening.
This is the first case of convulsions related to the use of SCRA described in Europe, and the first case of convulsions related to the use the SCRA AM-2201 confirmed by analysis of biological samples. It is important for emergency physicians, clinical toxicologists and clinical pharmacologists managing those presenting with acute toxicity related to the use of SCRA to analytically confirm the exact compound(s) involved, to enable accurate description of the acute toxicity associated with individual SCRA.
KeywordsSpice K2 Synthetic cannabinoid receptor agonist SCRA AM-2201 Recreational drugs Cannabis
Conflicts of interest
D.M.W. and P.I.D. have acted as scientific advisors to the UK Advisory Council on the Misuse of Drugs (ACMD) and the European Monitoring Centre for Drugs and Drug Abuse (EMCDDA).
- 1.Home Office Statistical Bulletin (2012) Drug Misuse Declared: Findings from the 2010/11 British Crime Survey Available from: http://www.homeoffice.gov.uk/publications/science-research-statistics/research-statistics/crime-research/hosb1211/hosb1211?view=Binary [Last accessed 19th March]
- 2.Wood DM, Ramsey J, Dargan PI (2008) Detecting novel and emerging recreational drugs on the ‘club scene’. Irish Psychiatrist 9:223–228Google Scholar
- 3.Wood DM, Measham F, Dargan PI (2012) ‘Our Favourite Drug’: Prevalence of use and preference for mephedrone in the London night-time economy 1 year after control. J Subs Use In pressGoogle Scholar
- 5.Dick D, Torrance C (2010) Drugs survey. MixMag 225:44–53Google Scholar
- 6.EMCDDA Annual Report 2011: Annual report on the state of the drugs problem in Europe. Available from: http://www.emcdda.europa.eu/attachements.cfm/att_143743_EN_EMCDDA_AR2011_EN.pdf [Last accessed 19th March 2012]
- 8.European Monitoring Centre for Drugs and Drug Addiction. Understanding the “Spice” Phenomenon (2009) Available from: http://www.emcdda.europa.eu/attachements.cfm/att_80086_EN_Spice%20Thematic%20paper%20%E2%80%94%20final%20version.pdf [Last accessed 19th March 2012]
- 10.Wood DM, Dargan PI (2012) Novel psychoactive substances: how to understand the acute toxicity associated with the use of these substances. Ther Drug Monitor In pressGoogle Scholar
- 16.Deluca P, Shifano F, Davey Z, Corazza O, di Furia L, Farre M et al (2009) Spice report by the psychonaut web mapping research project. Institute of Psychiatry, King’ s College London, LondonGoogle Scholar
- 19.Banerji S, Deutsch CM, Bronstein AC (2010) Spice ain’t so nice. Clin Toxicol 48:632Google Scholar
- 24.Canning JC, Ruha A-M, Pierce R, Torrey M, Reinhart SJ (2010) Severe gi distress after smoking JWH-018. Clin Toxicol 48:618Google Scholar